source
- Rintatolimod Plus Pembrolizumab and Cisplatin Displays 50% ORR in Recurrent Ovarian CancerThe addition of rintatolimod to pembrolizumab and cisplatin demonstrated robust albeit preliminary antitumor activity in patients with recurrent ovarian cancer.onclive · 2mo ago↗ source
- Drugmakers have to go through rigorous tests to get a lower tariff rateLanding a reduced 20% tariff rate will require pharma companies to fill out extensive paperwork and be closely monitored by the Department of Commerce. President Donald Trump signed an executive or…Endpoints · 2mo ago↗ source
- Dana-Farber Study Finds Stage IV Breast Cancer Increasing in Incidence and Proportion Over the Last DecadeA Dana-Farber study showed cases of stage IV breast cancer are increasing in incidence and as a proportion of all breast cancer diagnoses.